Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) EBITDA Margin (2016 - 2025)

Perspective Therapeutics' EBITDA Margin history spans 15 years, with the latest figure at 14652.77% for Q4 2024.

  • For Q4 2024, EBITDA Margin fell 1489096.0% year-over-year to 14652.77%; the TTM value through Sep 2025 reached 35977.2%, down 3749121.0%, while the annual FY2024 figure was 6464.15%, 360913.0% down from the prior year.
  • EBITDA Margin for Q4 2024 was 14652.77% at Perspective Therapeutics, down from 6211.33% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 238.19% in Q4 2023 and bottomed at 14652.77% in Q4 2024.
  • The 5-year median for EBITDA Margin is 88.69% (2021), against an average of 1583.18%.
  • The largest annual shift saw EBITDA Margin skyrocketed 4763bps in 2021 before it crashed -1489096bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 37.01% in 2020, then skyrocketed by 129bps to 10.62% in 2021, then crashed by -2408bps to 245.08% in 2022, then skyrocketed by 197bps to 238.19% in 2023, then crashed by -6252bps to 14652.77% in 2024.
  • Per Business Quant, the three most recent readings for CATX's EBITDA Margin are 14652.77% (Q4 2024), 6211.33% (Q3 2024), and 2835.59% (Q2 2024).